Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 03, 2021 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
February 23, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

REDWOOD CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
February 05, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
January 28, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
January 04, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
December 11, 2020 08:30 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
November 10, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
November 03, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
October 29, 2020 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting

REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...